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Successful, safe pharmacological treatment of atrial fibril-lation (AF) is a primary yet unmet need in cardiovascular 
medicine.1 Patients with AF exhibit largely variable disease char-
acteristics and continue to be at high risk for hospitalizations, 
heart failure, and stroke as a result of the limited effectiveness of 
unspecific pharmacological or interventional treatment. Patient-
tailored therapy is required to improve the outcomes of patients 
with AF. However, mechanism-based approaches are currently 
limited by an insufficient understanding of precise molecular 
remodeling associated with AF. Shortening of action potential 
(AP) duration (APD) is considered a hallmark of atrial remod-
eling in AF that promotes re-entry, supporting the perpetuation 
of the arrhythmia.2 The therapeutic significance of accelerated 
atrial repolarization is highlighted by AF suppression through 
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inhibition of repolarizing K+ currents by class III antiarrhythmic 
drugs or via targeted gene transfer.3,4 Although constitutive IK,ACh 
activity, increased IK1 current, and decreased ICa,L have previously 
been implicated in APD shortening during AF, the contribution 
of other ion channels is poorly understood.2,5–8
Two-pore-domain K+ (K2P) channels facilitate AP repo-
larization, and regulation of K2P currents dynamically deter-
mines cellular excitability.9–16 Specifically, cardiac K2P3.1 
(TASK-1 [tandem of P domains in a weak inward-rectifying 
K+ channel–related acid-sensitive K+ channel-1]) currents are 
implicated in AP regulation and may contribute to AF.17–22 
Inhibition or genetic inactivation of cardiac K2P3.1 channels 
results in APD prolongation in rodents.17–20 In the human 
heart, K2P3.1 K+ channels are expressed predominantly in the 
atria and could serve as atrium-specific antiarrhythmic targets 
for AF therapy.23,24 A role for cardiac K2P3.1 channels as drug 
targets is further supported by their sensitivity to established 
antiarrhythmic compounds.25–29 The aim of this study was to 
explore the potential contribution of K2P3.1 current dysregu-
lation to AF-related APD abbreviation and to assess the rel-
evance of K2P3.1 inhibition for mechanism-based therapy in 
patients with paroxysmal AF (pAF) and chronic AF (cAF).
Methods
Study Patients
A total of 122 patients (mean age, 68±12 years; male/female, 83/39) 
with sinus rhythm (SR; n=39), pAF (n=39), and cAF (ie, persistent, 
long-standing persistent, or permanent AF; n=44) undergoing open 
heart surgery for coronary artery bypass grafting or valve repair/
replacement were included (Table). Tissue samples were obtained 
from the right or left atrial appendage. For comparison, left ventricu-
lar (LV) tissue samples were acquired from 5 patients with ischemic 
or dilated cardiomyopathy during LV assist device implantation to 
evaluate ventricular expression levels. All patients received sevoflu-
rane for general anesthesia. The study protocol involving human tis-
sue samples was approved by the ethics committees of the University 
of Heidelberg (Germany; Medical Faculty Heidelberg, S-017/2013; 
Medical Faculty Mannheim, 2011-216 N-MA), the University of 
Frankfurt am Main (Germany; 53/08), and the University of Szeged 
(Hungary; license number 717, reference number 63/97). Written 
informed consent was obtained from all patients, and the study was 
conducted in accordance with the Declaration of Helsinki.
Quantitative Real-Time Polymerase Chain Reaction
Quantitative real-time polymerase chain reaction was performed with 
the StepOnePlus (Applied Biosystems, Foster City, CA) polymerase 
chain reaction system according to the manufacturer’s protocol. All 
quantitative real-time polymerase chain reactions were performed in 
triplicate (see Table I in the online-only Data Supplement for primer 
information), and control experiments in the absence of cDNA were 
included. Data are expressed as an average of triplicates.
Western Blot Analysis
Protein immunodetection was performed by SDS gel electrophoresis 
and Western blotting with primary antibodies directed against K2P3.1 (1:200; APC-024; Alomone Labs, Jerusalem, Israel), as described.30–33 
Protein content was normalized to GAPDH.
Isolation of Atrial Myocytes
Myocytes were enzymatically dispersed with collagenase essen-
tially as reported (see Supplemental Methods in the online-only Data 
Supplement for details).34,35
Cellular Electrophysiology
Current and membrane potential recordings from cardiac myo-
cytes were carried out at room temperature (21°C–25°C) with an 
RK-400 amplifier (Bio-Logic SAS) using the whole-cell patch clamp 
configuration as published.15 The K2P3.1 channel inhibitor A293 {2-(butane-1-sulfonylamino)-N-[1-(R)-(6-methoxypyridin-3-yl)-
propyl]-benzamide}17 (kindly provided by Sanofi-Aventis, Berlin, 
Germany) was applied to isolate K2P3.1 current. A293 was dissolved 
in dimethyl sulfoxide to a stock solution of 10 mmol/L and stored at 
−20°C. Cardiac APs were recorded from freshly isolated myocytes 
using the whole-cell patch-clamp technique at room temperature 
(21°C–25°C). APs were elicited in current-clamp mode with a hold-
ing current of −40 pA by injection of brief current pulses (2 millisec-
onds, 1 nA) at a 0.2-Hz stimulation rate.
Computational Modeling
The SR and cAF versions of the Grandi et al36 computational model 
of the human atrial cardiomyocyte, including our recent update with 
Na+-dependent regulation of IK1 and IK,ACh,37 was extended with a for-
mulation for the K2P3.1 current (Supplemental Methods, Table II, and 
Figure I in the online-only Data Supplement).
Data Acquisition and Statistical Analysis
Data acquisition was performed with pClamp software (Molecular 
Devices, Sunnyvale, CA). Origin 6 (OriginLab, Northampton, MA) 
software was used for data analysis. Patient data are expressed as 
mean±SD. Data obtained from patch-clamp recordings are provided 
as mean±SEM. Statistical significance between means of continuous 
variables was evaluated with the Student t tests. Values of P<0.05 
were considered statistically significant. Multiple comparisons were 
performed with 1-way ANOVA. The Bonferroni adjustment was used 
for post hoc testing. If a quantity was dependent on 2 attributes (ie, to 
analyze correlations between channel expression and rhythm or LV 
function), we performed a 2-factor ANOVA to assess the main effects 
of the factors and their interaction. Similarly, 2-factor repeated-mea-
sures ANOVA was applied when multiple measurements were taken 
on individual myocytes at different membrane voltages. To test for 
rank-order correlation, we calculated the Kendall τ.
Results
K2P Channel Expression in the Human Heart
A comprehensive expression analysis of all human K2P iso-
forms identified K2P1.1 and K2P3.1 as predominant K2P sub-
units in the right and left atria of patients with SR (n=14; 
Figure 1). K2P3.1 channels were studied in detail in the present 
study owing to robust atrial expression in combination with 
pronounced AF-associated remodeling that was unique among 
K2P channels (Figure 1). In LV tissue samples (n=5), K2P3.1 
transcript levels were low compared with the right atrium 
(16-fold; n=5–10; P<0.0001) and left atrium (14-fold; n=4; 
P=0.066; Figure 1). For comparison, ion channel genes with 
established significance in human atrial electrophysiology and 
arrhythmogenesis were analyzed, revealing that atrial K2P3.1 
mRNA expression was similar to K
v
4.3 channels conducting 
the cardiac transient outward K+ current and to inward-recti-
fier potassium channels Kir2.2 and Kir2.3 (Figure 2).
Increased K2P3.1 Levels Contribute to Atrial 
Remodeling in Patients With cAF 
Remodeling of ion channel expression is generally believed 
to constitute the electric substrate that shortens atrial APD, 
supporting AF-maintaining re-entry. We found that K2P3.1 
mRNA expression in the right atrium was elevated by 59.8% 
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(P=0.030) in patients with cAF (n=10) compared with individu-
als with SR (n=10; Figure 1). In addition, there was a 27.6% 
increase of K2P3.1 mRNA levels in left atrial tissue (cAF, n=11 
versus SR, n=4) that was not statistically significant (P=0.55; 
Figure 1). In contrast, K2P3.1 mRNA levels did not change in 
patients with pAF (n=16) compared with patients in SR (n=14; 
Figure 1). Alterations of K2P3.1 mRNA expression levels were 
consistent with K2P3.1 immunoblots (Figure 3 and Figure II in 
the online-only Data Supplement). cAF was associated with 
upregulation of K2P3.1 immunoreactivity at 50 to 55 kDa, cor-
responding to the fully processed membrane protein, in the right 
atrium by 64.0±17.7% (P=0.025; n=4) compared with patients 
in SR (Figure 3A–3C). We also observed a moderate increase in 
K2P3.1 protein expression in pAF (37.4±13.1%; P=0.043; n=4). 
Of note, K2P3.1 immunosignal intensity at ≈200 kDa, which may 
reflect channel aggregates, was similarly upregulated in patients 
with cAF (Figure 3A). Low protein levels were detected by 
anti-K2P3.1 antibodies in an exemplary ventricular sample, high-
lighting weak K2P3.1 expression in LV tissue (Figure IIIA in the 
online-only Data Supplement). However, limited discrimination 
of K2P3.1 and other cardiac proteins by anti-K2P3.1 antibodies in 
mice requires cautious attention in the interpretation of human 
Western blot data (the online-only Data Supplement provides an 
in-depth appraisal of antibody specificity).
In addition to K2P3.1, K2P channels K2P13.1 and K2P17.1 
were significantly affected in patients with cAF, displaying 
reduced mRNA levels in the right atrium (Figure 1). cAF 
was further associated with significant upregulation (Kir2.1; 
KCNQ1) or suppression (sulfonylurea receptor 1, potassium 
channel-interacting protein 2, Kir3.1, Kir3.4) of additional ion 
Table.  Baseline Characteristics of Study Patients
RAA LAA
SR
(n=35)
pAF
(n=33)
cAF
(n=33)
SR
(n=4)
pAF
(n=6)
cAF
(n=11)
Demographics
  Men, n (%) 25 (71) 19 (76) 26 (79) 3 (75) 4 (67) 6 (55)
  Age, y 63.7±13.8 71.7±12.6* 70.3±7.9 63.0±2.9 64.8±11.6 70.3±5.7
  Body mass index, kg/m² 28.1±4.8 27.9±4.6 27.9±5.3 NA NA NA
  Height, cm 170±9.6 171±10.7 173±7.8 NA NA NA
Medical history, n (%)
  CAD 24 (69) 21 (64) 19 (58) 0 (0) 0 (0)† 0 (0)†
  AVD 15 (43) 16 (49) 24 (73)* 0 (0) 0 (0) 0 (0)†
  MVD 0 (0) 0 (0) 0 (0) 4 (100) 6 (100)† 11 (100) †
  CAD+AVD 4 (11) 4 (12) 10 (30) 0 (0) 0 (0) 0 (0)
  Hypertension 34 (97) 28 (85) 31 (94) 3 (75) 0 (0) *† 4 (36)†
  Diabetes mellitus 12 (34) 7 (21) 10 (30) 1 (25) 0 (0) 3 (27)
  Hyperlipidemia 25 (71) 21 (64) 27 (82) 1 (25) 1 (17) 6 (55)
LVEF, n (%)
  Normal 21 (60) 15 (45) 10 (30)* 2 (50) 4 (67) 7 (64)
  Mild reduced 6 (17) 7 (21) 7 (21) 0 (0) 0 (0) 4 (36)
  Moderate reduced 5 (14) 6 (18) 10 (30) 1 (25) 2 (33) 0 (0)
  Severe reduced 3 (9) 5 (15) 6 (18) 1 (25) 0 (0) 0 (0)
Concomitant medication, n (%)
  Digitalis 1 (3) 3 (9) 7 (21) * 0 (0) 1 (17) 2 (18)
  ACE inhibitors 22 (63) 16 (49) 14 (42) 4 (100) 3 (50) 9 (82)†
  AT1 antagonists 6 (17) 5 (15) 7 (21) NA NA NA
  β-Blockers 24 (69) 25 (76) 24 (73) 3 (75) 5 (83) 6 (55)
  Diuretics 13 (37) 20 (61) 28 (85) * NA NA NA
  Nitrates 0 (0) 3 (9) 2 (6) NA NA NA
  Lipid-lowering drugs 22 (63) 24 (73) 20 (61) 2 (50) 1 (17)† 5 (46)
  OAC 9 (26) 22 (67) * 23 (70) * 2 (50) 5 (83) 9 (82)
ACE indicates angiotensin-converting enzyme; AT1, angiotensin receptor-1; AVD, aortic valve disease; CAD, coronary 
artery disease; cAF, chronic atrial fibrillation; LAA, left atrial appendage; LVEF, left ventricular ejection fraction (normal, 
≥55%; mild impairment, 45%–54%; moderate impairment, 30%–44%; severe impairment, <30%); MVD, mitral valve 
disease; NA, not available; OAC, oral anticoagulation; pAF, paroxysmal atrial fibrillation; RAA, right atrial appendage; and 
SR, sinus rhythm.
*P<0.05 vs SR, †P<0.05 versus corresponding values in the RA from ANOVA followed by Bonferroni multiple-
comparisons procedure for continuous variables and from the Fisher exact test for categorical variables.
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channels and accessory subunits relevant to atrial electro-
physiology (Figure 2). Of note, we did not detect significant 
electric remodeling in patients with pAF.
K2P3.1 Current Enhancement in cAF
Functional consequences of K2P3.1 upregulation were studied 
in right atrial myocytes obtained from patients with SR, pAF, 
and cAF. K2P3.1 current was isolated by use of the experimen-
tal compound A293, which specifically inhibits the channels 
at 200 nmol/L (Figure 4A; see also Supplemental Results and 
Figure IV in the online-only Data Supplement).18,24 A293-
sensitive K+ currents activated at potentials >−20 mV and 
showed Goldman-Hodgkin-Katz (open or outward) rectifi-
cation that is characteristic of K2P channels (Figure 4B–4F). 
K2P3.1 current density quantified at 40 mV was increased 
by 3.1-fold in patients with cAF (n=13 cells obtained from 
N=5 individuals) compared with SR (n/N=17/6; P=0.002; 
Figure 4F and 4G; see Figure V in the online-only Data 
Supplement for absolute current values and cell capacitance 
data). K2P3.1 currents tended to be 1.5-fold higher in pAF sub-jects (n/N=13/6) in relation to SR (n/N=17/6) without statisti-
cal significance (P=0.47; Figure 4E and 4G).
K2P3.1 Upregulation Is Associated With APD 
Shortening
Upregulation of K2P3.1 mRNA, protein, and corresponding 
currents in cAF suggest functional relevance in shaping the 
atrial AP. Atrial APs were studied under current-clamp con-
ditions in human atrial myocytes. APD at 90% of repolar-
ization (APD90) was abbreviated by 42.9% from 213.0±11.1 
milliseconds (SR; n/N=9/6) to 121.7±12.6 milliseconds 
(cAF; n/N=10/6; P<0.0001; Figure 5A, 5C, and 5E) in cAF, 
consistent with the increase in repolarizing K2P3.1 currents. 
In patients with pAF (n/N=9/5), APD90 remained virtually 
unchanged in relation to SR (P=0.67; Figure 5B, 5D, and 
5E). There was no rhythm-dependent modulation of APD 
at 50% of repolarization (APD50; Figure 5A–5D) or rest-
ing membrane potential (Figure V in the online-only Data 
Supplement) in any group.
Class III Antiarrhythmic Effects of K2P3.1 Channel 
Inhibition in cAF Patients
The experimental K2P3.1 inhibitor A293 was used to test 
the hypothesis that pharmacological K2P3.1 reduction would 
reverse APD shortening in cAF. In human atrial myocytes 
obtained from patients in SR (n/N=9/6), K2P3.1 block by 
200 nmol/L A293 induced only a weak prolongation of 
APD50 (3.4±1.6%; P=0.11) and APD90 (17.1±4.5%; P=0.012; 
Figure 5A and 5D–5F). In contrast, APD90 was markedly 
prolonged by 57.9±10.0% (n/N=10/6) in cAF (200 nmol/L 
A293; P<0.0001), indicating significant class III antiarrhyth-
mic efficacy in this subset of patients with AF (Figure 5C, 5E, 
and 5F). A293 also increased APD90 in pAF, albeit to a lesser 
degree (27.8±6.3%; P=0.003; Figure 5B, 5E, and 5F). A direct 
Figure 1. Cardiac expression and remodeling of K2P channel mRNA in patients with sinus rhythm (SR), paroxysmal atrial fibrillation (pAF), 
and chronic atrial fibrillation (cAF). Ventricular samples (VS) were analyzed for comparison. Insets represent selective enlargements to 
visualize transcript levels of subunits with low expression. Note that the function of K2P1.1, K2P7.1, K2P12.1, and K2P15.1 protein has not 
been unequivocally established to date. Data are expressed as mean±SEM arbitrary units normalized to IPO8. IPO8 indicates importin 
8; LAA, left atrial appendage; LV, left ventricle; and RAA, right atrial appendage. *P<0.05, **P<0.01, ***P<0.001 vs RAA/SR; #P<0.05, 
##P<0.01, ###P<0.001 vs LAA/SR.
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comparison of the A293 effects between patients with SR, 
pAF, and cAF revealed that specific K2P3.1 blockade had little 
effect on absolute APD90 in SR and pAF (Figure 5E), whereas 
in patients with cAF, A293 increased APD90 to APD levels 
typical for SR subjects (Figure 5E and 5F).
Computational Analysis of the Effect of K2P3.1 
Current on APD in SR and cAF
The Grandi et al36 computational model of the human atrial 
cardiomyocyte was extended with a formulation for the K2P3.1 
current based on the experimentally measured I-V relation-
ship (Figure I in the online-only Data Supplement). The SR 
and cAF versions of the model were adjusted to reproduce the 
experimental APD50 and APD90 under simulated conditions 
corresponding to the experimentally used pipette and bath 
solutions (Figure 6A and 6B). Simulated inhibition of K2P3.1 
channels produced a modest prolongation of APD90 in the 
SR model but a much larger prolongation in the cAF model 
(Figure 6A and 6C), consistent with experimental results. 
Moreover, this APD prolongation was observed at all pacing 
frequencies between 0.2 and 3.3 Hz (Figure 6D). Finally, APD 
in the cAF model after K2P3.1 channel blockade approached 
that of the SR model, with a reduction in the APD difference 
from 93.2 to 28.1 milliseconds (−70%) after K2P3.1 channel 
blockade compared with SR simulations. Together, these data 
suggest that, under these conditions, upregulation of K2P3.1 
in patients with cAF plays a major role in the proarrhythmic 
APD shortening.
Figure 2. Atrial expression profile of indicated ion channel subunits in patients with sinus rhythm (SR), paroxysmal atrial fibrillation (pAF), 
and chronic atrial fibrillation (cAF). Data obtained from ventricular samples (VS) were analyzed for reference. Insets represent selective 
enlargements to visualize low-level transcripts. Data are expressed as mean±SEM arbitrary units normalized to IPO8. ANP indicates atrial 
natriuretic peptide; Cx40, connexin40; Cx43, connexin43; hERG, human ether-a-go-go–related gene; IPO8, importin 8; KChIP, potassium 
channel-interacting protein; LAA, left atrial appendage; LV, left ventricle; minK, minimal K+ channel; MiRP, minK-related peptide; NCX, 
sodium-calcium exchanger; RAA, right atrial appendage; and SUR, sulfonylurea receptor. *P<0.05, **P<0.01, ***P<0.001 vs RAA/SR; 
#P<0.05, ##P<0.01, ###P<0.001 vs LAA/SR.
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Independent Effects of Cardiac Function on Atrial 
K2P3.1 Expression
To provide a more precise characterization of the patient 
population likely to benefit from K2P3.1 blockade, the correla-
tion of right atrial K2P3.1 expression levels with LV function 
was explored. Patient groups with SR (n=16), pAF (n=12), 
and cAF (n=11) were analyzed. Study subgroups were not 
significantly different with respect to sex, body mass index, 
or medical history. The potential relationship between K2P3.1 
levels and LV function or rhythm was statistically analyzed 
via 2-way ANOVA with rhythm status (SR, pAF, cAF) and LV 
function (normal; mild, moderate, severe reduction) as fac-
tors. The analysis revealed a significant association between 
LV function of study patients and K2P3.1 expression (F=53.6; 
P=0.006; Figure 7A). Atrial K2P3.1 levels were significantly 
downregulated in patients with severe LV function impair-
ment regardless of the rhythm status compared with no, mild, 
and medium impairment (P=0.047; Figure 7A). This is in 
contrast to the correlation between rhythm status and K2P3.1 
expression (F=42.3; P=0.026) characterized by cAF-associ-
ated upregulation (P=0.022; Figure 7B). There was no sig-
nificant correlation between LV function and cardiac rhythm 
(F=11.8; P=0.35; Kendall τ=−0.16) in the patient cohort.
Discussion
Atrial K2P3.1 K+ Channels in Humans With SR
K2P potassium channels conduct repolarizing currents and 
contribute to the resting membrane voltage in excitable cells.9 
In the present work, we delineated mRNA expression of mul-
tiple K2P channels in left and right atria obtained from control 
subjects with SR. K2P3.1 displayed highest transcript levels 
among K2P family members with confirmed K+ channel func-
tion (ie, after exclusion of K2P1.1, K2P7.1, K2P12.1, and K2P15.1 
subunits, which do not produce substantial K+ currents) and 
was specifically studied. The high ratio of atrial to ventricu-
lar K2P3.1 transcripts (16:1) highlighted predominantly atrial 
expression. Inhibition of K2P3.1 current produced a tendency 
toward prolonged APD90 by 17% in patients in SR, reflecting 
class III antiarrhythmic effects. These data indicate that K2P3.1 
functionally contributes to the atrial AP in subjects with SR 
and represents an atrium-selective target for antiarrhythmic 
therapy.
APD Shortening in cAF Patients: Significance of 
K2P3.1 and Comparison With Previous Studies
Electric remodeling of human atrial tissue is a hallmark of 
AF pathophysiology, stabilizing re-entrant circuits via abbre-
viation of atrial APD.2 We observed significant shortening of 
APD90 in patients with cAF compared with subjects with SR. In 
contrast, there was no APD reduction in pAF cardiomyocytes, 
in accordance with previous data.38 In addition, the patients’ 
rhythm status was not associated with atrial resting membrane 
potential changes in the present study consistent with earlier 
work.35,38,39 Similarly, inhibition of K2P3.1 current had no effect 
on resting membrane potential. The molecular basis of elec-
tric remodeling was further elucidated in a comprehensive 
approach that included all K2P channels and 21 additional ion 
channel subunits relevant to atrial electrophysiology. The main 
finding was a significant upregulation of K2P3.1 expression 
and current levels in patients with cAF but not in patients with 
pAF, suggesting a mechanistic explanation for the typical APD 
shortening in patients with cAF. The presence of noninactivat-
ing outward K+ currents in patient-derived atrial myocytes after 
extensive pharmacological block of established potassium 
channels additionally highlights a significant contribution of 
K2P3.1 conductance to human cardiac electrophysiology.40
AF-associated APD shortening has previously been 
attributed to increased IK1 current, downregulation of ICa,L, 
and constitutively active IK,ACh (despite decreased Kir3.1 
and Kir3.4 subunits underlying the current).2,41,42 In the pres-
ent cAF cohort, APD abbreviation was linked to increased 
Kir2.1 and KCNQ1 channel expression, in addition to K2P3.1 
upregulation. Expression of the L-type calcium channel α 
subunit Ca
v
1.2 was not significantly altered, suggesting that 
the reduction of ICa,L is not caused primarily by downregula-
tion of the expression of its α subunit.2 Furthermore, there 
was significant downregulation of repolarizing K+ channels 
Figure 3. Western blot analysis of K2P3.1 protein in human right 
atrium. A, Representative immunoblots obtained from patients in 
sinus rhythm (SR), paroxysmal atrial fibrillation (pAF), or chronic 
atrial fibrillation (cAF) probed with anti-K2P3.1 antibodies.  
B, Anti-GAPDH antibodies were applied to quantify protein load. 
C, Mean±SEM optical density values normalized to GAPDH 
expression of indicated patient groups (n=4 subjects per group; 
*P<0.05 vs SR).
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(Kir3.1, Kir3.4, Kv4.3), which is consistent with previous data 
and would prolong rather than shorten atrial APD. We conclude 
that K2P3.1 upregulation, in combination with increased Kir2.1 
and KCNQ1 levels, accounts for APD shortening in patients 
with cAF. AF-related K2P3.1 dysregulation and APD shorten-
ing strongly suggest a mechanistic role in cAF perpetuation 
with implications for patient-tailored antiarrhythmic therapy.
Therapeutic Implications: K2P3.1 Inhibition 
Provides Mechanism-Based AF Management
Atrial selectivity is a desired target in the development of 
novel compounds for AF. Limiting the electropharmacological 
action to atrial tissue reduces the risk of proarrhythmic effects 
in the ventricles.23 Inhibitors of K2P3.1 channels, which are 
expressed predominantly in human atria and enhanced in AF, 
are therefore expected to be particularly effective and safe in 
AF therapy. In addition, the ability of an antiarrhythmic inter-
vention to prevent AF depends on its capacity to suppress 
the underlying disease mechanism. Specifically, the reversal 
of atrial remodeling by targeting substrate development has 
become a focus of attempts at therapeutic intervention. The 
present study reveals K2P3.1 current upregulation as a distinct 
arrhythmogenic substrate in cAF associated with abbrevi-
ated APD. Antiarrhythmic drugs with class III characteristics 
Figure 4. K2P3.1 current properties in sinus rhythm (SR), paroxysmal atrial fibrillation (pAF), and chronic atrial fibrillation (cAF).  
A, Specificity of the K2P3.1 inhibitor A293 assessed in Xenopus oocytes (n=4–14 cells were studied; see the online-only Data Supplement 
for details). Significant current reduction was observed with human K2P3.1 and related, noncardiac K2P9.1 channels. B through  
D, Representative macroscopic currents recorded from human right atrial myocytes using indicated voltage protocols and corresponding 
mean step current density as a function of the respective test potentials are displayed (top to bottom) for SR (B), pAF (C), and cAF (D). 
K2P3.1 current was isolated with the use of the specific inhibitor A293. E and F, Current-voltage relationships of mean A293-sensitive 
current density obtained in B through D are depicted compared with SR for patients with pAF (E) and cAF (F). G, Mean A293-sensitive 
current density quantified at 40-mV membrane potential. Data are expressed as mean±SEM. n/N indicates number of myocytes/number 
of patients. *P<0.05, **P<0.01, ***P<0.001 vs drug-free control conditions (A) or vs SR (E–G).
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suppress AF through K+ channel inhibition, resulting in pro-
longation of APD and prevention of electric re-entry. Here, 
specific K2P3.1 inhibition by 200 nmol/L A293 prolonged the 
APD in patients with cAF to achieve levels observed in SR 
subjects, resulting in functional correction of electric remod-
eling in this AF subentity. Finally, diminished K2P3.1 expres-
sion in AF subentities with severely reduced LVEF provides 
a criterion for personalized antiarrhythmic therapy: Clinical 
efficacy of K2P3.1 inhibition is expected primarily in patients 
with cAF and normal or mildly to moderately reduced LVEF. 
Studies in large animals and humans are required next to fur-
ther explore this novel antiarrhythmic paradigm in vivo.
Potential Limitations
AF-associated electric remodeling was studied in right and left 
atrial appendage tissue, revealing a previously unrecognized 
mechanism of AF pathophysiology. It remains unclear whether 
the results may be extrapolated to other atrial regions that have 
not been specifically assessed owing to the limited availability of 
these samples. Statistically significant K2P3.1 upregulation was 
detected in right atrial tissue only (Figure 1). However, there was 
also a tendency toward increased K2P3.1 mRNA levels in left 
atrial tissue obtained from patients with cAF that did not reach 
formal significance owing to a single outlier in the SR group. 
Thus, we suggest that K2P3.1 enhancement is likely to occur in 
left atrial tissue as well, indicating that therapeutic interventions 
targeting K2P3.1 upregulation in patients with cAF may be effec-
tive in both right and left atrial tissue.
Study patients were carefully matched for baseline charac-
teristics, medication, and concomitant heart disease to exclude 
any bias associated with these conditions. In particular, no 
patient received class I or class III antiarrhythmic therapy that 
may have modulated APD. There were minor intergroup dif-
ferences in age, cardiac function, cardiovascular disease, or 
medication as potential confounding factors that require con-
sideration in the interpretation of our results. However, K2P3.1 
enhancement may not be attributed to impaired LVEF because 
we observed a correlation of severely reduced LV function 
with decreased rather than increased K2P3.1 levels.
We did not investigate constitutive IK,ACh activity that was 
previously implicated in APD shortening. Given that selective 
K2P3.1 inhibition by A293 in patients with cAF fully recon-
stituted APD, the contribution of constitutive IK,ACh activity to 
APD appears to be minor in the present subentity of patients 
with cAF. Unspecific antibody detection of cardiac protein 
observed in knockout mice requires consideration in the inter-
pretation of human K2P3.1 immunoblot data (Supplemental 
Results, Table III, and Figure III in the online-only Data 
Supplement).19 We cannot fully exclude that available K2P3.1 
antibodies, including those used in this work, which were 
previously applied to demonstrate cardiac K2P3.1 expression 
in mice, rats, dogs, and humans (Table III in the online-only 
Data Supplement), may recognize other proteins in humans 
as well. Therefore, the additional confirmation of increased 
K2P3.1 expression at the protein level needs to be interpreted 
with caution. In human ventricular tissue, low protein levels 
Figure 5. Characteristics of action potentials (APs) and electropharmacological effects of K2P3.1 current blockade in right atrial 
myocytes. A through C, Representative APs recorded at 0.2 Hz in the absence or presence of A293 are shown for sinus rhythm (SR; A), 
paroxysmal atrial fibrillation (pAF; B), and chronic atrial fibrillation (cAF; C) patients. D and E, Corresponding mean AP durations at 50% of 
repolarization (APD50; D) and 90% repolarization (APD90; E) at baseline and after specific K2P3.1 inhibition with 200 nmol/L A293.  
F, Relative APD50 and APD90 after application of 200 nmol/L A293 in atrial myocytes obtained from patients with indicated cardiac rhythm 
(values were normalized to respective baseline APD in the absence of A293). Data are provided as mean±SEM. n/N indicates number of 
myocytes/number of patients. *P<0.05, ***P<0.001 vs drug-free control conditions; #P<0.05, ##P<0.01, ###P<0.001 vs SR.
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were detected by anti-K2P3.1 antibodies, arguing against rele-
vant cross-reactivity with endogenous human cardiac protein.
Altered ion channel transcript and protein levels analyzed 
in cardiac tissue may reflect alterations not only in myocytes 
but also in fibroblasts and other cell types. Importantly, in 
the present work, electrophysiological recordings provide 
unequivocal confirmation of K2P3.1 current and APD remod-
eling in atrial myocytes.
Finally, structural alterations of atrial tissue may con-
tribute to the development and maintenance of AF, in addi-
tion to electric remodeling.1,2,31,33 Specifically, atrial fibrosis, 
which has been implicated in conduction heterogeneity and 
Figure 6. Computational analysis of the impact of K2P3.1 channels on action potential duration (APD). A, Action potential (top) and 
K2P3.1 current (bottom) in the sinus rhythm (SR; left) and chronic atrial fibrillation (cAF; right) models under control conditions (solid 
lines) or after complete inhibition of K2P3.1 current (dashed lines). Data were obtained at a pacing frequency of 0.2 Hz with intracellular 
and extracellular ion concentrations based on the experimental pipette and bath solutions. B, Validation of APD at 50% of repolarization 
(APD50; top) and APD at 90% (APD90; bottom) in the SR and cAF models under control conditions and after K2P3.1 blockade (solid bars) 
compared with measurements in isolated human atrial cardiomyocytes from patients with SR and cAF in the absence or presence of 
200 nmol/L A293 (open bars). Experimental data are identical to those in Figure 5. C, Validation of the relative prolongation of APD50 and 
APD90 as a result of K2P3.1 channel blockade based on the data from B. D, Rate dependence of APD prolongation after K2P3.1 blockade in 
the SR (open symbols) and cAF models (solid symbols) with dynamic intracellular ion concentrations.
Figure 7. Correlation of right atrial K2P3.1 mRNA 
levels with cardiac function. A, K2P3.1 mRNA 
expression in subjects with normal left ventricular 
ejection fraction (LVEF) and with mildly, moderately, 
or severely impaired LVEF. B, Transcript levels in 
patients with sinus rhythm (SR), paroxysmal atrial 
fibrillation (pAF), and chronic atrial fibrillation (cAF). 
Data are expressed as mean±SEM arbitrary units 
normalized to importin 8 (IPO8). *P<0.05 vs normal/
mildly impaired/moderately reduced LVEF (A) or vs 
SR/pAF (B).
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in the promotion of AF, is commonly observed in human 
AF and in animal models. Structural remodeling was not 
addressed here because the present study focused on the 
contribution of K2P3.1 current dysregulation to electric 
remodeling only.
Conclusions
The data provide novel mechanistic insights into atrial 
arrhythmogenesis in humans. We detailed increased atrial 
K2P3.1 expression and function in patients with cAF that 
resulted in shortening of AP recorded from patient-derived 
atrial myocytes. Specific K2P3.1 inhibition prolonged APD in 
cardiac myocytes obtained from patients with cAF to recon-
stitute levels of SR subjects. Functional correction of atrial 
ionic remodeling through K2P3.1 channel blockade represents 
a novel paradigm to optimize and specify AF management.
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CLINICAL PERSPECTIvE
Mechanism-based approaches to atrial fibrillation (AF) therapy are sought to increase effectiveness and to provide more indi-
vidualized patient care. Specifically, the reversal of atrial remodeling by targeting substrate development has become a focus 
of attempts at therapeutic intervention. Shortening of atrial refractory periods promotes electric re-entry and contributes 
to maintenance of AF. Outward currents mediated by K2P3.1 (TASK-1) 2-pore-domain potassium (K2P) channels promote 
repolarization and have been implicated in action potential (AP) regulation in animal models. Their functional contribution 
to atrial electrophysiology in patients with AF, however, is not known. The present work provides novel mechanistic insights 
into atrial arrhythmogenesis in humans. Cellular electrophysiology, molecular biology, biochemistry, and computational 
modeling were used to assess the significance of K2P3.1 channels and their remodeling in patients with paroxysmal and 
persistent, long-standing persistent, or permanent (chronic) AF compared with subjects in sinus rhythm. K2P3.1 subunits 
exhibited predominant atrial expression. We observed increased K2P3.1 expression and function in patients with chronic AF 
that resulted in shortening of AP duration in patient-derived atrial myocytes. In patients with paroxysmal AF, K2P3.1 levels 
were not significantly affected, in line with a lack of AP duration changes. Pharmacological K2P3.1 inhibition prolonged AP 
duration in cardiac myocytes obtained from patients with chronic AF to reconstitute levels of subjects in sinus rhythm. This 
work provides the first direct evidence of K2P3.1 dysregulation resulting in AP duration shortening in patients with chronic 
AF, suggesting a mechanistic role of K2P3.1 in chronic AF perpetuation. Functional correction of atrial ionic remodeling 
through K2P3.1 blockade represents a novel paradigm to optimize and specify AF management.
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